Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 Pharmacokinetics with Oral Contraceptive and Gastric Emptying in Overweight/Obese Women
NCT07710729Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UBT251 in obesity, sponsored by Novo Nordisk. Primary endpoints: Area under the ethinylestradiol plasma concentration time curve at steady state and Area under the levonorgestrel plasma concentration time curve at steady state. Started Jul 2026; status: recruiting.
02
Drugs
UBT251
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07710729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710729.